Pharmacovigilance Market was valued at US$ 8.5 billion in 2024 and is projected to grow at a CAGR of 8.4% to reach US$ 19.1 billion by 2034.

1
GLOBAL PHARMACOVIGILANCE MARKET
(2018-2030)
Report

2
USE THIS REPORT TO:
• Develop an understanding of the current market dynamics and growth opportunities
• Understand an in-depth analysis and market forecast for the pharmacovigilance
market
• Analyze the competitive landscape, including key strategies and recent developments
of the top vendors in the pharmacovigilance market
• Get an understanding of recent developments in the pharmacovigilance market
REPORT ID:
Domain: Healthcare
Sub-domain: Pharmaceuticals
Base Year: 2017
Historical Period: 2012-2020
Forecast Period: 2021-2030
Industry Reports | Consulting | Intelligence Center
+ 1 860 531 2701|
sales@prophecymarketinsights.com |
www.prophecymarketinsights.com
Report

3
1. INTRODUCTION
1.1 Market Definition
1.2 Scope of the Study
1.3 Study Deliverables
1.4 StudyAssumptions
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 Current Market Scenario
5.2 Industry Attractiveness – Porter’s Five ForcesAnalysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
4. Threat of Substitute Products and Services
5. Degree of Competition
TABLE OF CONTENTS
Report
6. MARKET DYNAMICS
6.1 Drivers
6.1.1 Increasing Drug Consumption and Drug Development
6.1.2 Increasing Incidences of ADR and Drug Toxicity
6.1.3 Growing Trend of Outsourcing Pharmacovigilance Services
6.2 Restraints
1. High Risk Associated with Data Security
2.Lack of Global Regulatory Harmonization
Standardization for Adverse Event Data Collection
and Data
6.3 Opportunities
6.3.1 Increasing Focus on Personalized Medicine
6.4 Challenges
6.4.1 Undeveloped Healthcare Infrastructure and Complexity in
Data Storage

4
TABLE OF CONTENTS
7. MARKET SEGMENTATION AND ANALYSIS
1. By Clinical Trial Phase
1. Preclinical
2. Phase I
3. Phase II
4. Phase III
5. Phase IV
2. By Service Provider
1. In-house
2. Contract Outsourcing
3. By Type of Reporting
1. Spontaneous Reporting
2. Intensified ADR Reporting
3. Targeted Spontaneous Reporting
4. Cohort Event Monitoring
5. EHR Mining
4. By End User
1. Hospitals
2. Pharmaceutical Companies
3. Others
5. By Geography
1. NorthAmerica
1. United States
2. Canada
3. Mexico
2. Europe
1. United Kingdom
2. Germany
3. France
4. Italy
5. Spain
6. Rest of Europe
3. Asia-Pacific
1. India
2. China
3. Japan
4. Australia
5. South Korea
6. Rest ofAsia-pacific
Report

5
4. SouthAmerica
1. Brazil
2. Argentina
3. Rest of SouthAmerica
5. Middle East & Africa
1. GCC
2. SouthAfrica
3. Rest of MEA
8. COMPETITIVE LANDSCAPE & COMPETITIVE LANDSCAPE
1. Accenture
Overview
Products and Strategies
SWOT
Recent Developments
2. Cognizant
Overview
SWOT
Recent Developments
3. Laboratory Corporation of America Holdings
TABLE OF CONTENTS
Overview
SWOT
Recent Developments
4. IBM Corporation
Overview
SWOT
Recent Developments
5. ArisGlobal
Overview
Recent Developments
6. Foresight Group InternationalAG
Overview
Recent Developments
7. ICON PLC
Overview
SWOT
Recent Developments
Report

6
TABLE OF CONTENTS
8. Capgemini
Overview
SWOT
Recent Developments
9. United BioSource Corporation
Overview
SWOT
Recent Developments
10. Wipro Ltd
Overview
SWOT
Recent Developments
11. BioClinica
Overview
Recent Developments
12. IT Clinical
Overview
Recent Developments
Report
9. FUTURE OF THE MARKET

8
• This report studies the global pharmacovigilance market. It includes a detailed analysis of spontaneous reporting, cohort event monitoring, and EHR mining.
• Pharmacovigilance refers to the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-
related problems. The focus of pharmacovigilance is on ADR (adverse drug reactions) and drug toxicity. The global pharmacovigilance market comprises all types
of adverse event reporting conducted during clinical trials in hospitals, pharmacies, and other healthcare sectors.
• The market has been segmented by clinical trial phase, service provider, type of reporting, and end user. By clinical trial phase, the market is segmented further,
into Preclinical, Phase I, Phase II, Phase III, And Phase IV.
• The market, on the basis of service providers, is segmented into in-house and contract outsourcing. By type of reporting, the market is segmented into
spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining.
• By end user, the market is segmented into pharmaceutical companies, academic research organization, and others.
• A holistic study of the market has been carried out, by incorporating various factors, extending from country-specific demographic conditions and business cycles
to market-specific microeconomic influences that were needed to analyze the future trends of the market. The research uncovers many paradigm shifts regarding
regional competitive advantage and dynamics in the market studied, primarily on the services
INTRODUCTION
Report
MARKET DEFINITION

9
GLOBAL
PHARMACOVIGILANCE
MARKET
By Clinical Trial Phase
Preclinical
Phase I
Phase II
Phase III
Phase IV
By Service Provider
In-house
Contract Outsourcing
By Type of Reporting
Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining
By End User
Hospitals
Pharmaceutical Companies
By Geography (with country-wise analysis)
Others
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
INTRODUCTION
Report
SCOPE OF THE STUDY

10
• Global- and regional-level analysis, along with forecast, for the market studied.
• Study of the effects of exogenous and endogenous factors, namely, demographic, economic, and political factors, among others, which may affect the global
market.
• Porter’s five forces framework, incorporating the factors influencing each force, to determine the intensity of competition.
• Segment- and sub-segment-level analysis of the market, for the review and forecast periods.
• Identification of key factors instrumental in changing the market scenario, exploiting new opportunities, and gaining a competitive edge.
• Analysis of key players, a detailed study of their current strategic interests, and key financial performance indicators.
• The market number provided for 2017 is based on the financials reported in the proxy statements of the major players tracked in this market.
INTRODUCTION
Report
STUDYASSUMPTIONS

11
STUDY PERIOD
AIM AND OBJECTIVE OF THE STUDY
FORECAST PERIOD
BASE YEAR
GEOGRAPHICAL SCOPE SEGMENTS COVERED
Global- and regional-level analysis, and forecast, of the pharmacovigilance market.
2015-2023 2017 2018-2030
MARKET DYNAMICS
INDUSTRYANALYSIS
SEGMENTANALYSIS
KEY VENDORS
COMPETITIVE LANDSCAPE
INTRODUCTION
Report
STUDY DELIVERABLES

12
2. RESEARCH METHODOLOGY
Report

13
• The research process adopted for this study is a highly structured, two-stage process: size
estimation of the review period and the market engineering for the forecast period, of the global-,
country-, and segment-level data, which leads to the data generation process (DGP) for the
studied variables.
• The size estimations are carried out through multiple bottom-up and top-down approaches. The
bottom-up approach includes, the examining of historical revenues of key players, studying the
size of the applications, value and supply chain analysis, and end-user demand, which are then
cross-validated against secondary and primary resources.
• The top-down approach is an astute research process, where the global market sizing is carried
out through the secondary research, validated then by primary industry experts.
Source: Prophecy Market Insights
• In this report, to analyze future trends, for the studied market during the forecast period, we have incorporated rigorous statistical and econometric methods,
which are further scrutinized by secondary and primary sources and by our in-house experts, supported by our extensive data intelligence repository.
• The market is studied holistically, from both the demand- and supply-side perspectives. This is carried out to analyze both end-user and producer behavior
patterns during the review period, which affect price, demand, and consumption trends. As the study demands analyzing long-term trends in the market, the
identification of factors influencing the market is based on the fundamentality of the market studied. Through secondary and primary researches, endogenous and
exogenous factors are identified, and are transformed to quantitative data through data extraction, which are then used for inferential purposes.
INTRODUCTION
Report

14
RESEARCH METHODOLOGY RESEARCH PHASES
SECONDARY
RESEARCH
DISCUSSION
GUIDE
PRIMARY
RESEARCH
ECONOMETRIC
MODELLING
EXPERT
VALIDATION
DATA
TRIANGULATION
REPORT
WRITING
• Doctors
• Sales Managers/ Product Managers
• Medical professionals
• External Subject-matter Experts
• Select Officials
• In-house Subject-matter Experts
• Insights from Data and
Forecasts are Compiled
• Statistical Reports
• Research Journals
• Government Publications
• News Articles and Press Releases
• Company-related Queries
• Market-related Queries
• Company Financials
• Forecasting Model
• Revalidation of Numbers through Primaries
• Combination of Top-down and Bottom-up
Approaches
6%
6%
20%
11%
26%
31%
Primary Interviews
CEOs/CFOs
Board Members
Research Heads
Strategic Decision Makers
Financial Advisors
Investors
55%
45%
Primary Interviews - Along the Value Chain
Manufacturers
End Users
Report

15
3. EXECUTIVE SUMMARY
Report

16
Pharmacovigilance Market: Revenue in USD
million, Global, 2015-2023
Key Findings
Global Pharmacovigilance Market
• The global pharmacovigilance market (henceforth referred to as the market studied) is
expected to witness a CAGR of 13.2%, over the forecast period.
2,994.2
3,388.7
3,835.4
4,342.0
xx
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
2015 2016 2017 2018 2023
Year
Revenue
(in
USD
million) EXECUTIVE SUMMARY
Report

18
• Due to the increasing number of investigative new drug (IND) applications being filed, the demand for pharmacovigilance is expected to grow at a steady
pace.
• The government initiatives in emerging economies, aimed at the promotion of drug discovery and healthcare advancement, are also expected to propel the
growth of the market.
• The strategic partnership among pharmaceutical companies and CROs is expected to have a significant impact on the growth of the market. North America
and Europe are the hubs of primary research on drug discovery.
• North America contributes the highest share in the global market. This is attributed to the concentration of drug manufacturing companies in this region. As
companies invest heavily on drug development, the usage of pharmacovigilance services is high in the United States.
• Increasing drug consumption and drug development, the increasing incidences of adverse drug reactions (ADR) and drug toxicity, and the increasing trend of
outsourcing pharmacovigilance services are the major factors contributing to the growth of the pharmacovigilance market in the forecast period.
• However, high risk associated with data security and lack of global regulatory harmonization and data standardization for adverse event data collection are the
major factors that restrict the growth of the market.
KEY INFERENCES
Report

19
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5. MARKET OVERVIEW
Report

20
The growth of the global
pharmacovigilance market is
due to the growing trend of
outsourcing pharmacovigilance
services. The cost of these
services is significantly lower in
developing regions, as
compared to developed regions.
The market is currently growing
also due to the increasing
incidences of adverse drug reaction
(ADR). It is estimated that ADR is
one of the leading causes of
deaths, after heart disease, cancer,
and stroke, globally. With the
increase in the number of cases of
ADR, there has been a significant
burden on the healthcare system.
The need to reduce the burden of
ADR has led to an increase in the
demand for pharmacovigilance
services.
The lack of global regulatory
harmonization and data
standardization for adverse event
data collection and high risk
associated with data security are
hindering the growth of the market
studied.
Accenture, Clinquest Group BV,
Cognizant, IBM Corporation,
Capgemini, and BioClinica are
some of the major players in the
market studied.
CURRENT MARKET SCENARIO
Report

21
THREAT OF NEW ENTRANTS
BENIGN AND
GROWING
THREAT OF SUBSTITUTES
LOW
MODERATE &
EVOLVING
BARGAINING
POWER OF
BUYERS
• The Porter’s five forces model studies the five identified competitive forces
that shape every industry and market, in order to determine the intensity of
the competition, and thus, the profitability and attractiveness of the industry.
The objective of the growth strategy is to adapt to these competitive forces
in a manner that may improve the position of the organization. This study
includes an exhaustive Porter’s five forces framework, incorporating the
factors influencing each force, to analyze the market from a microeconomic
perspective.
• In the study, Porter’s five forces are analyzed considering the factors
influencing each force and quantifying the factors through primaries and
quantitative analysis. The quantified factors are further mapped out to
derive the impact of each force on competitive dynamics.
HIGH
COMPETITIVE RIVARLY
MODERATE
BARGAINING
POWER OF
SUPPLIERS
MARKET INSIGHTS
Report
PORTER’S FIVE FORCES
ANALYSIS

22
• There is a high level of capital investment involved in
setting up pharmacovigilance services, and it needs
the involvement and coordination of IT and CSV teams
to support the system, in order to meet business
requirements and grant infrastructure availability and
performance standards.
• There are various government regulatory requirements
that are need to be met for pharmacovigilance services
to function.
• Threat of new entrants is Low.
MARKET INSIGHTS PORTER’S FIVE FORCES
ANALYSIS
THREAT OF NEW ENTRANTS
Government
policy
10
9
8
7
6
5
4
3
2
1
0
Capital
requirements
Economies of
scale
Economies of
product
differences
Product
differentiation
Switching costs or sunk
costs
Access to
distribution
Industry profitability
(Market
CAGR)
Report

23
MARKET INSIGHTS
PORTER’S FIVE FORCES
ANALYSIS
BARGAINING POWER OF BUYERS
Buyer concentration to
firm concentration
ratio
10
9
8
7
6
5
4
3
2
1
0
Report
Degree of dependency
upon existing channels
of distribution
Bargaining leverage,
particularly in
industries with high
fixed costs
Buyer switching costs
relative to firm
switching costs
Buyer
information
availability
Force down
prices
Availability of
existing
substitute
products
Buyer price
sensitivity
Differential
advantage
(uniqueness) of
industry products

27
6.1 Drivers
6.2 Restraints
6.4 Challenges
6. MARKET DYNAMICS
6.3 Opportunities
Report

28
Impact
Market Drivers
Market Restraints
Impact
INCREASING INCIDENCES OF
ADR AND DRUG TOXICITY
HIGH RISK ASSOCIATED WITH
DATA SECURITY
INCREASING DRUG
CONSUMPTION AND DRUG
DEVELOPMENT
High
Low
Low
High
GROWING TREND OF
OUTSOURCING
PHARMACOVIGILANCE
SERVICES
LACK OF GLOBAL REGULATORY
HARMONIZATION AND DATA
STANDARDIZATION FOR ADVERSE
EVENT DATA COLLECTION
MARKET DYNAMICS
Report
DRIVERS, RESTRAINTS &
OPPORTUNITIES

29
• Increasing incidences of lifestyle diseases, such as diabetes, hypertension, and cardiac disorders, as a result of sedentary lifestyle, lack of physical activities,
changing lifestyle patterns, and poor diet lead to the increased consumption of drugs, which, in turn, augments the demand for drug monitoring and further fuels
the growth of the market studied.
• As of 2012, 117 million people were suffering from chronic disorders, such as heart disease, stroke, cancer, Type 2 diabetes, obesity, and arthritis, which increased
the consumption of drugs.
• With growing drug consumption, the need for regular monitoring of drugs has also increased, thereby boosting the market studied. Owing to changing climate,
infectious diseases are also on the rise. Increasing urbanization also causes a surge in drug consumption and drug development, developing the need to have
them regulated.
• The drug development process is subjected to a strict regulatory regime that is evolving continuously, and therefore causes major focus on pharmacovigilance
services. The major factor driving the pharmacovigilance market is the growth of drug development processes as a result of the increasing number of health
disorders.
• The large number of pipeline drugs also contribute substantial growth to the pharmacovigilance market, as they help understand the adverse actions and side-
effects of drugs. There were 7,493 drugs in pre-clinical phase in the year 2017, and this is projected to reach 8,040 in 2018. These statistics indicate increasing
focus on pharmacovigilance services.
INCREASING DRUG CONSUMPTION AND DRUG DEVELOPMENT
MARKET DYNAMICS
Report
DRIVERS

36
7. SEGMENTATION
MARKET SEGMENTATION
Report
1. By Clinical Trial Phase
2. By Service Provider
7.3 By Type of Reporting
4. By End User
5. By Geography

37
7.1 SEGMENTATION – BY CLINICAL TRIAL PHASE
MARKET SEGMENTATION
Report
BY CLINICAL TRIAL PHASE
1. Preclinical
2. Phase I
7.1.3 Phase II
4. Phase III
5. Phase IV

38
Pharmacovigilance Market : Revenue in USD million,
by Clinical Trial, Global, 2015-2023
6.0%
3.5%
20.0%
70.2%
Pharmacovigilance Market:
Revenue Share (%), by Clinical Trial, Global, 2017
0.5%
Preclinical Phase I Phase II Phase III Phase IV
MARKET SEGMENTATION BY CLINICAL TRIAL PHASE
CLINICAL TRIAL 2015 2016 2017 2018 2023 CAGR (%)
Preclinical xx xx xx xx xx xx
Phase I xx xx xx xx xx xx
Phase II xx xx xx xx xx xx
Phase III xx xx xx xx xx xx
Phase IV xx xx xx xx xx xx
Report

39
Year
MARKET
SEGMENTATION
CLINICAL TRIAL PHASE PRECLINICAL
15.0
16.5
18.2
xx
xx
0
5
10
15
20
25
30
35
2015 2016 2017 2018 2023
Fig.3 Pharmacovigilance Market: Revenue in USD million,
Preclinical, Global, 2015-2023
Revenue
(in
USD
million)
Report

40
.
MARKET
SEGMENTATION
CLINICAL TRIAL PHASE PHASE I
Fig.4 Pharmacovigilance Market: Revenue in USD million, Phase I,
Global, 2015-2023
500
179.6
xx
xx
xx
0
50
100
150
200
250
300
350
400
450
2015 2016 2017 2018 2023
Year
Revenue
(in
USD
million)
Report

41
2018 2023
MARKET
SEGMENTATION
CLINICAL TRIAL PHASE PHASE II
104.8
xx
xx
xx
Fig.5 Pharmacovigilance Market: Revenue in USD million, Phase II,
Global, 2015-2023
0
50
100
150
200
250
300
2015 2016 2017
Year
Revenue
(in
USD
million)
Report

42
2017 2018 2023
Year
MARKET
SEGMENTATION
CLINICAL TRIAL PHASE PHASE III
598.8
676.9
xx
xx
xx
0
200
400
600
800
1000
1200
1400
1600
Phase III, Global, 2015-2023
1800
2015 2016
Revenue
(in
USD
million)
Report

43
• This phase is also considered as the late phase or post-marketing surveillance. Phase IV
studies are done to collect information on the drug's effect on various populations, in terms
of any side effects associated with its long-term use.
Year
MARKET
SEGMENTATION
CLINICAL TRIAL PHASE PHASE IV
2095.9
2374.6
2690.6
xx
xx
0
1000
2000
3000
4000
5000
6000
2015 2016 2017 2018 2023
Revenue
(in
USD
million)
Phase IV, Global, 2015-2023
Report

44
7.2.1 In-house
7.2 SEGMENTATION – BY SERVICE PROVIDER
MARKET SEGMENTATION
Report
BY SERVICE PROVIDER
7.2.2 Contract Outsourcing

45
REGION 2015 2016 2017 2018 2023 CAGR (%)
In-house xx xx xx xx xx xx
Contract Outsourcing xx xx xx xx xx xx
Fig.8 Pharmacovigilance Market : Revenue in USD billion, by Service
Provider, Global, 2015-2023
36.3%
63.8%
In-house Contract Outsourcing
MARKET SEGMENTATION BY SERVICE PROVIDER
Fig.9 Pharmacovigilance Market : Revenue Share (%), by Service
Provider, Global, 2017
Report

46
Year
MARKET
SEGMENTATION
BY SERVICE PROVIDER IN-HOUSE
1197.7
1291.9
1390.3
xx
xx
0
500
1000
1500
2000
2500
2015 2016 2017 2018 2023
Revenue
(in
USD
million)
Fig.10 Pharmacovigilance Market: Revenue in USD
million, In-house, Global, 2015-2023
Report

47
.
Fig.11 Pharmacovigilance Market: Revenue in USD million, Contract
Outsourcing, Global, 2015-2023
MARKET
SEGMENTATION BY SERVICE PROVIDER
CONTRACT
OUTSOURCING
1796.5
2096.8
xx
xx
xx
0
1000
2000
3000
4000
5000
6000
7000
2015 2016 2017 2018 2023
Year
Revenue
(in
USD
million)
Report

48
7.3 SEGMENTATION – BY TYPE OF REPORTING
MARKET SEGMENTATION
Report
BY TYPE OF REPORTING
1. Spontaneous Reporting
2. Intensified ADR Reporting
7.3.3 Targeted Spontaneous Reporting
4. Cohort Event Monitoring
5. EHR Mining

49
TYPE OF REPORTING 2015 2016 2017 2018 2023 CAGR (%)
Spontaneous Reporting xx xx xx xx xx xx
Intensified ADR Reporting xx xx xx xx xx xx
Targeted Spontaneous
Reporting
xx xx xx xx xx xx
Cohort Event Monitoring xx xx xx xx xx xx
EHR Mining xx xx xx xx xx xx
Fig.12 Pharmacovigilance Market : Revenue in USD billion,
by Type of Reporting, Global, 2015-2023
xx
xx
xx
xx
xx
Fig.13 Pharmacovigilance Market :
Revenue Share (%), by Type of Reporting, Global, 2017
Spontaneous Reporting
Targeted Spontaneous Reporting
EHR Mining
Intensified ADR Reporting
Cohort Event Monitoring
MARKET SEGMENTATION BY TYPE OF REPORTING
Report

50
2017 2018 2023
Year
MARKET SEGMENTATION BY TYPE OF REPORTING SPONTANEOUS REPORTING
1347.4
1527.9
1732.7
xx
xx
0
500
1000
1500
2000
2500
3000
3500
4000
2015 2016
Revenue
(in
USD
million)
Spontaneous Reporting, Global, 2015-2023
Report

51
Year
MARKET SEGMENTATION BY TYPE OF REPORTING INTENSIFIED ADR REPORTING
329.4
371.5
419.0
xx
xx
100
0
200
300
400
500
600
700
800
900
Intensified ADR Reporting, Global, 2015-2023
1000
2015 2016 2017 2018 2023
Revenue
(in
USD
million)
Report

52
Year
MARKET SEGMENTATION BY TYPE OF REPORTING TARGETED SPONTANEOUS REPORTING
209.6
235.9
x
xx
xx
0
100
200
300
400
500
600
2015 2016 2017 2018 2023
Revenue
(in
USD
million)
Targeted Spontaneous Reporting , Global, 2015-2023
Report

53
2017 2018 2023
Year
MARKET SEGMENTATION BY TYPE OF REPORTING COHORT EVENT MONITORING
688.7
xx
xx
xx
xx
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2015 2016
Revenue
(in
USD
million)
Cohort Event Monitoring, Global, 2015-2023
Report

54
2017 2018 2023
Year
MARKET SEGMENTATION BY TYPE OF REPORTING EHR MINING
419.2
474.0
xx
xx
xx
0
200
400
600
800
1000
1200
2015 2016
Revenue
(in
USD
million)
by Type of Reporting, EHR mining, Global, 2015-2023
Report

55
7.4 SEGMENTATION – BY END USER
MARKET SEGMENTATION
Report
BY END USER
7.4.1 Hospitals
7.4.2 Pharmaceutical Companies
7.4.3 Others

56
END USER 2015 2016 2017 2018 2023 CAGR (%)
Hospitals xx xx xx xx xx xx
Pharmaceutical
Companies
xx xx xx xx xx xx
Others xx xx xx xx xx xx
Fig.1 Pharmacovigilance Market : Revenue in USD billion,
by End User, Global, 2015-2023
xx
xx
xx
Fig.1 Pharmacovigilance Market :
Revenue Share (%), by End User, Global, 2017
Hospitals Pharmaceutical Companies Others
MARKET SEGMENTATION BY END USER
Report

57
MARKET SEGMENTATION BY END USER HOSPITALS
598.8
677.7
xx
xx
xx
0
200
400
600
800
1000
1200
1400
1600
Pharmacovigilance Market: Revenue in USD million, by End
User, Hospitals, Global, 2015-2023
1800
2015 2016 2017 2018 2023
Year
Revenue
(in
USD
million)
Report

58
2017 2018 2023
Year
MARKET SEGMENTATION BY END USER PHARMACEUTICAL COMPANIES
xx
xx
xx
xx
xx
0
1000
2000
3000
4000
5000
6000
7000
2015 2016
Revenue
(in
USD
million)
User, Pharmaceutical Companies, Global, 2015-2023
Report

59
Year
MARKET SEGMENTATION BY END USER OTHERS
xx
xx
xx
xx
xx
0
50
100
150
200
250
300
350
User, Others, Global, 2015-2023
400
2015 2016 2017 2018 2023
Revenue
(in
USD
million)
Report

60
7.5 BY GEOGRAPHY
MARKET SEGMENTATION
Report
BY GEOGRAPHY
1. North America
2. Europe
7.5.3 Asia-Pacific
4. Middle East & Africa
5. South America

61
REGION 2015 2016 2017 2018 2023 CAGR (%)
North America xx xx xx xx xx xx
Europe xx xx xx xx xx xx
Asia-Pacific xx xx xx xx xx xx
Latin America xx xx xx xx xx xx
Middle East & Africa xx xx xx xx xx xx
Pharmacovigilance Market : Revenue in USD billion,
by Region, Global, 2015-2023
xx
xx
xx
xx
xx%
Pharmacovigilance Market:
Revenue Share (%), by Region, Global, 2017
North America Europe Asia-Pacific South America Middle East & Africa
MARKET SEGMENTATION BY GEOGRAPHY
Report

62
South
America
Europe
North
America
xx%
Middle
East &
Africa
xx%
xx%
xx%
xx%
Asia-
Pacific
MARKET SEGMENTATION
Report
BY GEOGRAPHY

63
7.5.1 NORTH AMERICA
Report
7.5.1.1 United States
7.5.1.2 Canada
7.5.1.3 Mexico

64
MARKET
SEGMENTATION
GEOGRAPHY NORTHAMERICA
COUNTRY 2015 2016 2017 2018 2023 CAGR (%)
United States xx xx xx xx xx xx
Canada xx xx xx xx xx xx
Mexico xx xx xx xx xx xx
Pharmacovigilance Market : Revenue in USD billion,
by Country, North America, 2015-2023
xx%
xx%
xx%
Pharmacovigilance Market: Revenue
Share (%), by Country, North America,
2017
US Canada Mexico
Report

65
Pharmacovigilance Market: : Revenue in USD million,
United States, 2015-2023
MARKET
SEGMENTATION
GEOGRAPHY NORTH AMERICA UNITED STATES
943.2
xx
xx
xx
xx
0
500
1000
1500
2000
2500
3000
2015 2016 2017 2018 2023
Year
Revenue
(in
USD
million)
Report

66
• The pharmacovigilance system, in Canada, is moving forward due to developed
healthcare, infrastructure, high healthcare expenditure, R&D spent for the
biopharmaceutical industry, subsidized public healthcare, lower labor rates, and
government support, such as easy funds for clinical trials.
MARKET
SEGMENTATION
GEOGRAPHY NORTH AMERICA CANADA
296.4
xx
xx
xx
xx
0
100
200
300
400
500
600
700
800
900
2015 2016 2017 2018 2023
Year
Revenue
(in
USD
million)
Canada, 2015-2023
Report

67
• The pharmacovigilance system is decentralized in Mexico. The national authority is
COFEPRIS (Federal Commission for the Protection against Sanitary Risk) founded
by the Mexican MoH, in 2001. With that there are several other institutions,
including National Pharmacovigilance Center, helping the pharmacovigilance
activities.
MARKET
SEGMENTATION
GEOGRAPHY NORTH AMERICA MEXICO
107.8
xx
xx
xx
xx
0
50
100
150
200
250
300
2015 2016 2017 2018 2023
Year
Revenue
(in
USD
million)
Mexico, 2015-2023
Report

94
8. COMPANY PROFILES &
COMPETITIVE LANDSCAPE
Report
1. Accenture
2. Cognizant
3. Laboratory Corporation of America Holdings
4. IBM Corporation
5. ArisGlobal
8.6 Foresight Group International AG
7. ICON PLC
8. Capgemini
9. United BioSource Corporation
10. Wipro Ltd
11. BioClinica
12. IT Clinical

95
31,048
32,883
34,850
2015 2016 2017
Total Revenue in USD million, 2015-2017
• Accenture is a global management consulting, technology services, and outsourcing company, with its presence in more
than 120 countries.
• In 2017, the company reported a net revenue of USD 34.7 billion, serving its clients in more than 200 cities. In 2015, the
company had about 130,000 employees in India, about 48,000 in the United States, and about 50,000 in the Philippines.
• Accenture works with Life Sciences clients in more than 50 countries, including pharmaceutical industry leaders, biotech
companies, medical device companies, and 125+ public health organizations. The life sciences industry helps to achieve
better pharmacovigilance through regulatory compliance, higher productivity, higher quality, and strategic safety outcomes.
• For four years in a row, Accenture has been named number one outsourcing company by International Association of
Outsourcing Professionals.
Financial Overview
1-312-842-5012
www.accenture.com
~ 435,000 Employees
HQ
Dublin, Ireland
Founded in 1787
Revenue (2017)
USD 34,850 million
Operations: Worldwide
COMPETITIVE
INTELLIGENCE
COMPANY
PROFILES
ACCENTURE OVERVIEW
USD 704 million R&D
USD 3,635million
Net Income(2017)
Report

96
• North America’s net revenue increased 4% in local
currency, driven by the United States.
• Europe’s net revenue increased 8% in local currency,
led by the United Kingdom and Germany, as well as
France, Spain, and Switzerland.
• Growth markets’ net revenue increased 12% in local
currency, led by Japan, as well as Australia,
Singapore, and China.
47%
34%
19%
North America
Europe
Growth Markets
Revenue Breakdown (%), by Geography, 2017
54%
46%
Consulting Outsourcing
Revenue Breakdown (%), by Type
of Work, 2017
20%
21%
18%
27%
14%
0.13%
Communications, Media &
Technology
Financial Services
Health & Public Service
Products
Resources
Other
Revenue Breakdown (%), by Division,
2017
• Communications, Media & Technology net revenues
increased 4% in local currency, led by Software &
Platforms in North America, as well as growth across all
industry groups in the growth markets. This growth was
partially offset by a decline in Communications & Media
in Europe, as disruptions in the market continue to impact
demand.
• Health & Public Service net revenues increased 3% in
local currency, driven by public service in growth markets
and Europe.
COMPETITIVE
INTELLIGENCE
Report
COMPANY
PROFILES
ACCENTURE OVERVIEW

97
• Safety Case Management
• Aggregate Reporting
• Literature Searching
• Deloitte Consulting LLP, Dorsey &
Whitney LLP
, Gartner Inc.,
International Business Machines
Corp., etc., pose competition in the
market.
• In the fiscal year 2017, the company continued to implement a strategy
focused on industry and technology differentiation, taking an increasingly
innovation-led approach to drive value for customers.
• As part of the growth strategy in 2017, it significantly increased
investments in strategic acquisitions—and also continued to invest in
assets and offerings, in branding and thought leadership, and in
attracting and developing talent—to further enhance differentiation and
competitiveness.
• To make them even more relevant and competitive, Accenture
continued to invest aggressively across the company—both
organically and through strategic acquisitions.
• In 2017, the company significantly stepped up its pace of
acquisitions, deploying approximately USD 1.7 billion across 37
transactions—nearly twice the investment in 2016.
Acquisitions
T
echnology
Products & Services
Competition
Strategies
COMPETITIVE
INTELLIGENCE
Report
COMPANY
PROFILES
ACCENTURE
PRODUCTS AND
STRATEGIES

98
• In terms of revenue it’s the world’s largest consulting firm, which
mainly focuses on IT and business consultancy.
• It has a large client base, and is a consultant to some of the top
companies.
• Accenture has a global service delivery network, with presence
in more than 200 cities and 56 countries.
Strengths
to other developing economies (market development),
Accenture can increase its revenue even more.
• More focus on technology and BPO, and making the
revenue equivalent to consulting, can help the firm to
penetrate the market even better. Also, this diversification
will provide a cushion during harsh financial times.
Opportunities
• By targeting small and mid-sized projects, and expanding
Threats
• Tough competition from IT giants, like IBM, Capgemeni, Infosys,
is the area of concern for the company.
• The recession period was tough for the company due to its over
dependability on premium clients. The large clients were the first
ones to be affected by the financial downturn. And hence,
Accenture’s revenue stream declined significantly. This is a
threat area that needs to be tackled for the future.
Weaknesses
• Accenture has 19 business units collaboratively working with
clients and with each other. This leads to conflicts due to lack of
internal coordination.
• Although its business is in management consulting, technology,
and BPO, but the consulting part forms the major source of
revenue for Accenture. This can be dangerous for the company in
the long run because running such a large operation requires that
the firm be ready for bad financial days.
COMPETITIVE
INTELLIGENCE
Report
COMPANY
PROFILES
ACCENTURE SWOT ANALYSIS

99
COMPETITIVE
INTELLIGENCE
COMPANY
PROFILES
ACCENTURE
RECENT
DEVELOPMENTS
M
M
Accenture and BioCelerate collaborated to advance
biopharmaceutical innovation through increased insights in R&D.
Apr 2017
M I E P
Mergers and
Acquisitions
Product
Innovation
Expansion Partnership
Accenture launched the Patient Experience Manager, which gave life
sciences companies a single view of patient interactions, enabling them to
make real-time improvements in the patient experience, by evaluating and
optimizing the effectiveness of each interaction.
Nov 2017
I
Accenture collaborated with Veeva Systems to advance regulatory
information management for the life sciences industry.
Oct 2017
Accenture introduced new analytics capabilities in the Accenture Life
Sciences Cloud for R&D.
Jun 2017
Accenture launched the intelligent patient service exchange to help life
sciences companies integrate technology solutions into its patient services
programs.
Feb 2017
I
I
Report

139
9. FUTURE OF THE MARKET
Report

140
FUTURE OF THE MARKET
Report

SOME OF OUR CLIENTS
EMISPDF in-pmi-01 from 103.203.66.214 on 2019-10-29 10:34:37 GMT. DownloadPDF.
Downloaded by in-pmi-01 from 103.203.66.214 at 2019-10-29 10:34:37 GMT. EMIS. Unauthorized Distribution Prohibited.

Adding to your revenues without being a cost.
Address: 964 E. BadilloStreet #2042 Covina, CA 91724
Rest of world: + 91 7775049802
Email:sales@prophecymarketinsights.com

Pharmacovigilance Market was valued at US$ 8.5 billion in 2024 and is projected to grow at a CAGR of 8.4% to reach US$ 19.1 billion by 2034.

Recommended

Recommended

More Related Content

Similar to Pharmacovigilance Market was valued at US$ 8.5 billion in 2024 and is projected to grow at a CAGR of 8.4% to reach US$ 19.1 billion by 2034.

Similar to Pharmacovigilance Market was valued at US$ 8.5 billion in 2024 and is projected to grow at a CAGR of 8.4% to reach US$ 19.1 billion by 2034. (20)

More from ankitakalvankar

More from ankitakalvankar (18)

Recently uploaded

Recently uploaded (20)

Pharmacovigilance Market was valued at US$ 8.5 billion in 2024 and is projected to grow at a CAGR of 8.4% to reach US$ 19.1 billion by 2034.